BMO Capital analyst George Farmer initiated with an Outperform rating and $75 price target. The analyst believes that NKTR-214 "may be just potent enough to meaningfully boost checkpoint inhibitor therapy for solid tumors," and estimates that if successful, "could top about $14B in peak sales with no meaningful competition for several years after launch."
https://thefly.com/landingPageNews.php?id=2868304
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.